SCHEMBL7739282

SCHEMBL7739282

CC(C)(C)[Si](C)(C)OCC1CCCC1

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 1/20 0.34
CYP1A2 P05177 1/20 0.32
TOP2A P11388 3/20 0.32
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7739318 0.98 CYP1A2 (0.35) FKBP1ACYP1A2TOP2APOLBGAA
SCHEMBL7739395 0.98 CYP1A2 (0.35) FKBP1ACYP1A2TOP2APOLBGAA
SCHEMBL7738582 0.98 CYP1A2 (0.35) FKBP1ACYP1A2TOP2APOLBGAA
SCHEMBL7738017 0.98 CYP1A2 (0.35) FKBP1ACYP1A2TOP2APOLBGAA
SCHEMBL7739287 0.98 CYP1A2 (0.35) FKBP1ACYP1A2TOP2APOLBGAA
SCHEMBL5673208 0.96 FKBP1A (0.37) FKBP1ATOP2A
Methyl Alcohol SCHEMBL5672666 0.92 FKBP1A (0.38) FKBP1ATOP2A
SCHEMBL8062803 0.91 FKBP1A (0.33) FKBP1ATOP2A
SCHEMBL12632024 0.91 FKBP1A (0.33) FKBP1ATOP2A
SCHEMBL24921214 0.83 FKBP1A (0.33) FKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-08-31 US disclosed
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase BIOCRYST PHARMACEUTICALS, INC. (US) 2023-05-30 US disclosed
US-20080064691-A1 Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity ASTRAZENECA AB (SE) 2008-03-13 US disclosed
US-6410748-B1 Alicycli c group-containing monomer KABUSHIKI KAISHA TOSHIBA (JP) 2002-06-25 US disclosed
US-6291129-B1 LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS KABUSHIKI KAISHA TOSHIBA (JP) 2001-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A FKBP1A 2917/4885CYP1A2 1726/4885TOP2A 1567/4885
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase ALK, ACVR2B, ACVR2A FKBP1A 2917/4885CYP1A2 1726/4885TOP2A 1567/4885
US-20080064691-A1 Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity PYGL, PYGM, GYS1 FKBP1A 3129/4885CYP1A2 742/4885TOP2A 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.